09/07/2025
Thank you to those who have expressed interest so far!
We could do with a few more models for this study.
Please get in touch for more information!
AQPHA™ Medical B.V. has recently developed PTMC Dermal Filler, which is a novel dermal filler consisting of poly(trimethylene carbonate) (PTMC) microspheres dispersed in a gel-carrier to correct moderate to severe nasolabial folds. This product is a natural and fully absorbing dermal filler intended for injection and longer lasting results. The formulation of this dermal filler has not yet been tested in humans. This study is being carried out to determine the safety and performance of PTMC Dermal Filler up to 24 months after treatment.
For this study, you must be completely healthy. You are not allowed to take part in the study if, but not limited to, you:
- Are a woman who is pregnant or breast feeding or planning to become pregnant during the study.
- Have scars, inflammation, infection or skin injury at the intended treatment sites.
- Have had laser treatment within the whole facial area within 6 months prior to study treatment.
- Have received mesotherapy under the orbital rim within 6 months or had meshing or threads under the orbital rim (eye socket).
- Have had previous tissue augmentation (bulking agents; fillers such as hyaluronic acid or autologous fat) for facial wrinkles and scars within 12 months at the mid-face.
- Have received tissue augmentation with semi-permanent implants under the orbital rim within 24 months.
- Have had previous tissue augmentation with permanent implants.
- Have received treatment of microdermabrasion or micro needling within the whole facial area within 3 months prior to treatment.
During the 24-month study, you may be eligible for a single treatment which will be provided at no cost to you.